PCAS: INAUGURATION OF A NEW WORKSHOP AT THE COUTERNE SITE

INAUGURATION OF A NEW WORKSHOP AT THE COUTERNE SITE

Longjumeau; June 28, 2016

PCAS (Euronext Paris: PCA - FR0000053514), a specialist in developing and producing complex molecules for life sciences and innovative technologies, today announced that it has recently commissioned a new industrial workshop at its site in Couterne (France's Orne region), featuring a combination of new technologies and the highest safety and quality standards.

Boasting a total surface area of 400 m², this workshop will offer an environment conforming to the GMP standard (Good Manufacturing Practice). The workshop is fitted with reactors for cryogenic applications, highly acidic environments and pressurized reactions, and will allow technicians to carry out chemical reactions at very low temperatures, which represents a cutting-edge technological asset for driving the PCAS development strategy, especially in the healthcare industry where demand for the production of high value-added pharmaceutical intermediates continues to grow.

After the workshop was commissioned a few weeks behind schedule due to the planned leading-edge technologies, the official inauguration was celebrated on Monday, June 20, 2016 by the PCAS management team and its Chairman Christian Moretti, as well as all the employees at the Couterne site. Several local officials graced the ceremony with their presence, including the Prefect for Orne, Mrs. Isabelle David, and Mr. Joaquim Pueyo, Deputy of the Orne First Constituency.

Vincent Touraille, Chief Executive Officer of PCAS, states: "We would like to thank all the people that took part in the event, especially all the employees at the site whose efforts were instrumental in achieving this investment. This new promising workshop paints a clear picture of the Group's ambition to raise the quality and productivity bar and its ability to address the increasingly high level of complexity of the molecules developed by our key international customers. With our hi-tech production facilities, the PCAS Group is poised to strengthen its partnerships with healthcare professionals, pharmaceutical laboratories and biotech firms."

About PCAS 
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers of a growing range of proprietary products and solutions in leading-edge segments and also includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. PCAS generated net sales of €179.1 million in 2015 and employs close to 900 people in six countries.

To find out more about PCAS, visit: www.pcas.com